
A ‘Grand Unified Theory' of Math Just Got a Little Bit Closer
The original version of this story appeared in Quanta Magazine.
In 1994, an earthquake of a proof shook up the mathematical world. The mathematician Andrew Wiles had finally settled Fermat's Last Theorem, a central problem in number theory that had remained open for over three centuries. The proof didn't just enthral mathematicians—it made the front page of The New York Times.
But to accomplish it, Wiles (with help from the mathematician Richard Taylor) first had to prove a more subtle intermediate statement—one with implications that extended beyond Fermat's puzzle.
This intermediate proof involved showing that an important kind of equation called an elliptic curve can always be tied to a completely different mathematical object called a modular form. Wiles and Taylor had essentially unlocked a portal between disparate mathematical realms, revealing that each looks like a distorted mirror image of the other. If mathematicians want to understand something about an elliptic curve, Wiles and Taylor showed, they can move into the world of modular forms, find and study their object's mirror image, then carry their conclusions back with them.
This connection between worlds, called 'modularity,' didn't just enable Wiles to prove Fermat's Last Theorem. Mathematicians soon used it to make progress on all sorts of previously intractable problems.
Modularity also forms the foundation of the Langlands program, a sweeping set of conjectures aimed at developing a 'grand unified theory' of mathematics. If the conjectures are true, then all sorts of equations beyond elliptic curves will be similarly tethered to objects in their mirror realm. Mathematicians will be able to jump between the worlds as they please to answer even more questions.
But proving the correspondence between elliptic curves and modular forms has been incredibly difficult. Many researchers thought that establishing some of these more complicated correspondences would be impossible.
Now, a team of four mathematicians has proved them wrong. In February, the quartet finally succeeded in extending the modularity connection from elliptic curves to more complicated equations called abelian surfaces. The team—Frank Calegari of the University of Chicago, George Boxer and Toby Gee of Imperial College London, and Vincent Pilloni of the French National Center for Scientific Research—proved that every abelian surface belonging to a certain major class can always be associated to a modular form.
Toby Gee, Frank Calegari, and Vincent Pilloni, along with George Boxer (not pictured), spent nearly a decade on the proof. Photographs: Courtesy of Toby Gee; Jayne Ion; MC
'We mostly believe that all the conjectures are true, but it's so exciting to see it actually realized,' said Ana Caraiani, a mathematician at Imperial College London. 'And in a case that you really thought was going to be out of reach.'
It's just the beginning of a hunt that will take years—mathematicians ultimately want to show modularity for every abelian surface. But the result can already help answer many open questions, just as proving modularity for elliptic curves opened up all sorts of new research directions. Through the Looking Glass
The elliptic curve is a particularly fundamental type of equation that uses just two variables— x and y . If you graph its solutions, you'll see what appear to be simple curves. But these solutions are interrelated in rich and complicated ways, and they show up in many of number theory's most important questions. The Birch and Swinnerton-Dyer conjecture, for instance—one of the toughest open problems in math, with a $1 million reward for whoever proves it first—is about the nature of solutions to elliptic curves.
Elliptic curves can be hard to study directly. So sometimes mathematicians prefer to approach them from a different angle.
That's where modular forms come in. A modular form is a highly symmetric function that appears in an ostensibly separate area of mathematical study called analysis. Because they exhibit so many nice symmetries, modular forms can be easier to work with.
At first, these objects seem as though they shouldn't be related. But Taylor and Wiles' proof revealed that every elliptic curve corresponds to a specific modular form. They have certain properties in common—for instance, a set of numbers that describes the solutions to an elliptic curve will also crop up in its associated modular form. Mathematicians can therefore use modular forms to gain new insights into elliptic curves.
But mathematicians think Taylor and Wiles' modularity theorem is just one instance of a universal fact. There's a much more general class of objects beyond elliptic curves. And all of these objects should also have a partner in the broader world of symmetric functions like modular forms. This, in essence, is what the Langlands program is all about.
An elliptic curve has only two variables— x and y —so it can be graphed on a flat sheet of paper. But if you add another variable, z , you get a curvy surface that lives in three-dimensional space. This more complicated object is called an abelian surface, and as with elliptic curves, its solutions have an ornate structure that mathematicians want to understand.
It seemed natural that abelian surfaces should correspond to more complicated types of modular forms. But the extra variable makes them much harder to construct and their solutions much harder to find. Proving that they, too, satisfy a modularity theorem seemed completely out of reach. 'It was a known problem not to think about, because people have thought about it and got stuck,' Gee said.
But Boxer, Calegari, Gee, and Pilloni wanted to try. Finding a Bridge
All four mathematicians were involved in research on the Langlands program, and they wanted to prove one of these conjectures for 'an object that actually turns up in real life, rather than some weird thing,' Calegari said.
Not only do abelian surfaces show up in real life—the real life of a mathematician, that is—but proving a modularity theorem about them would open new mathematical doors. 'There are lots of things you can do if you have this statement that you have no chance of doing otherwise,' Calegari said.
'After a coffee, we would always joke that we had to go back to the mine.'
The mathematicians started working together in 2016, hoping to follow the same steps that Taylor and Wiles had in their proof about elliptic curves. But every one of those steps was much more complicated for abelian surfaces.
So they focused on a particular type of abelian surface, called an ordinary abelian surface, that was easier to work with. For any such surface, there's a set of numbers that describes the structure of its solutions. If they could show that the same set of numbers could also be derived from a modular form, they'd be done. The numbers would serve as a unique tag, allowing them to pair each of their abelian surfaces with a modular form.
The problem was that while these numbers are straightforward to compute for a given abelian surface, mathematicians don't know how to construct a modular form with the exact same tag. Modular forms are simply too difficult to build when the requirements are so constrained. 'The objects you're looking for, you don't really know they exist,' Pilloni said.
Instead, the mathematicians showed that it would be enough to construct a modular form whose numbers matched those of the abelian surface in a weaker sense. The modular form's numbers only had to be equivalent in the realm of what's known as clock arithmetic.
Imagine a clock: If the hour hand starts at 10 and four hours pass, the clock will point to 2. But clock arithmetic can be done with any number, not just (as in the case of real-world clocks) the number 12.
Boxer, Calegari, Gee, and Pilloni only needed to show that their two sets of numbers matched when they used a clock that goes up to 3. This meant that, for a given abelian surface, the mathematicians had more flexibility when it came to building the associated modular form.
But even this proved too difficult.
Then they stumbled on a trove of modular forms whose corresponding numbers were easy to calculate—so long as they defined their numbers according to a clock that goes up to 2. But the abelian surface needed one that goes up to 3.
The mathematicians had an idea of how to roughly bridge these two different clocks. But they didn't know how to make the connection airtight so they could find a true match for the abelian surface in the world of modular forms. Then a new piece of mathematics appeared that turned out to be just what they needed.
Lue Pan's work in a seemingly disparate area of number theory turned out to be essential. Photograph: Will Crow/ Princeton University Surprise Help
In 2020, a number theorist named Lue Pan posted a proof about modular forms that didn't initially seem connected to the quartet's problem. But they soon recognized that the techniques he'd developed were surprisingly relevant. 'I didn't expect that,' Pan said.
After years of regular meetings, mostly on Zoom, the mathematicians started to make progress adapting Pan's techniques, but major hurdles remained. Then, in the summer of 2023, Boxer, Gee, and Pilloni saw a conference in Bonn, Germany, as the perfect opportunity to come together. The only problem was that Calegari was supposed to travel to China at the same time to give a talk. But a difficult visit to the Chinese consulate in Chicago made him reconsider. 'Eight hours later, my visa was rejected and my car was towed,' he said. He decided to scrap the China talk and join his collaborators in Germany.
Gee secured the team a room in the basement of the Hausdorff Research Institute, where they were unlikely to be disturbed by itinerant mathematicians. There, they spent an entire week working on Pan's theorem, one 12-hour day after the next, only coming up to ground level occasionally for caffeine. 'After a coffee, we would always joke that we had to go back to the mine,' Pilloni said.
The grind paid off. 'There were many twists to come later,' Calegari said, 'but at the end of that week I thought we more or less had it.'
It took another year and a half to turn Calegari's conviction into a 230-page proof, which they posted online in February. Putting all the pieces together, they'd proved that any ordinary abelian surface has an associated modular form.
Their new portal could one day be as powerful as Taylor and Wiles' result, revealing more about abelian surfaces than anyone thought possible. But first, the team will have to extend their result to non-ordinary abelian surfaces. They've teamed up with Pan to continue the hunt. 'Ten years from now, I'd be surprised if we haven't found almost all of them,' Gee said.
The work has also allowed mathematicians to formulate new conjectures—such as an analogue of the Birch and Swinnerton-Dyer conjecture that involves abelian surfaces instead of elliptic curves. 'Now we at least know that the analogue makes sense' for these ordinary surfaces, said Andrew Sutherland, a mathematician at the Massachusetts Institute of Technology. 'Previously we did not know that.'
'Lots of things that I had dreamed we would be able to one day prove are now within reach because of this theorem,' he added. 'It changes things.'
Original story reprinted with permission from Quanta Magazine, an editorially independent publication of the Simons Foundation whose mission is to enhance public understanding of science by covering research developments and trends in mathematics and the physical and life sciences.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
RFK Jr. cancels at least $500M in mRNA vaccine funding. What are the implications?
The Department of Health and Human Services (HHS) announced this week it is beginning a "coordinated wind-down" of federally funded mRNA vaccine development. This includes terminating awards and contracts with pharmaceutical companies and universities and canceling 22 investment projects worth nearly $500 million. While some final-stage contracts will be allowed to be completed, no new mRNA-based projects will be initiated, the HHS said. "We reviewed the science, listened to the experts, and acted," Secretary Robert F. Kennedy Jr. said in a press release on Tuesday. "The data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate." MORE: What we know about the safety, efficacy of mRNA vaccines amid recent scrutiny Infectious disease experts told ABC News that mRNA technology has been very successful in preventing severe disease, hospitalization and deaths, especially during the COVID-19 pandemic, potentially affecting our preparedness for future pandemics. Ending mRNA vaccine development may also squash enthusiasm for technology that has been hailed as a potential promise for cancer and HIV vaccines. "It's an excellent technology. It saved millions of lives and did it in a remarkably safe manner," Dr. Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia, told ABC News. "I think it's an unscientific move, a move that goes against existing science." Affecting future pandemic preparedness Last year, the federal government awarded Moderna $176 million to help expedite the development of an mRNA-based bird flu vaccine. Earlier this year, the vaccine manufacturer received an additional $590 million to speed up the development. However, in its press release, the HHS said it was cancelling the award, which has been issued by the Biomedical Advanced Research and Development Authority, to Moderna and the University of Texas Medical Branch. Dr. Peter Hotez, a professor of pediatrics and molecular virology at Baylor College of Medicine in Houston, told ABC News the wind-down is a blow to pandemic preparedness. During the COVID-19 pandemic, mRNA technology demonstrated its ability to scale up vaccine production quickly. "The message to the companies will clearly be that they can no longer rely on the U.S. government for supporting any mRNA vaccine work, which is unfortunate, or even tragic, because the mRNA platform is one of the few that we have for pandemic threats in terms of something that we can make a vaccine for very quickly," he said. "So what, what Mr. Kennedy's and HHS' actions are doing is weakening our pandemic preparedness and weakening our biosecurity." The HHS also said it was terminating contracts with Emory University and Tiba Biotech. Researchers had been working on using mRNA technology to develop a nasal influenza vaccine. Emory has also been working on a dry powder inhaled mRNA-based treatment for influenza and COVID with TFF Pharmaceuticals, funded by BARDA. It's unclear if this is one of the 22 contracts that have been canceled. MORE: What to know about the next generation of COVID-19 vaccines Hotez said COVID-19 and influenza can have very severe consequences and that it's incorrect for Kennedy to mischaracterize them as harmless upper respiratory infections. "COVID and flu are not [only] upper respiratory infections," he said. "The reason we develop vaccines for COVID and flu is because they cause systemic illness and lower respiratory infections and cardiovascular illness. … This is part of the anti-vaccine playbook, to diminish the severity of the illness, and to say something like influenza or COVID is an upper respiratory infection, it's just very, very misleading." Cancer vaccines, HIV treatments mRNA technology has also been hailed as a potential vector for providing personalized cancer treatments and protection against HIV transmission. In February, a small preliminary study published in the journal Nature found a personalized mRNA vaccine may reduce the risks of pancreatic cancer returning after surgery. Additionally, a University of Florida study found an experimental mRNA vaccine paired with anticancer drugs boosted an anti-tumor response. Meanwhile, earlier this month, an early-stage clinical trial found two mRNA vaccine candidates triggered a strong immune response against HIV. Results from the trial showed that 80% of participants who received one of two vaccine candidates produced antibodies. Although antiretroviral therapy has been the standard treatment for HIV infection, and is effective in preventing transmission, it is hard to scale up worldwide due to its costs, making mRNA vaccines to be anti-HIV vaccine strategy, researchers from the U.S., Germany and Romania wrote in a commentary in June 2022. It's unclear if any of the BARDA contracts are specifically for cancer vaccines or HIV vaccine development, but Hotez said the real damage is denigrating mRNA technology. "What he's done is he's caused uncertainty among the American people about the safety and effectiveness of mRNA for any condition, including cancer," he said. "And in fact, mRNA technology is probably the most exciting technology we have now for cancer and also other non-communicable illnesses. … Even though he may not be canceling any cancer vaccine contracts through BARDA, it may have collateral deleterious in terms of squashing enthusiasm for the technology." Offit added that mRNA is not brand-new technology. mRNA was discovered independently by two teams in 1961, including French and American molecular biologists. Breakthroughs in developing mRNA vaccines began in the early 2000s, eventually leading to the development of COVID-19 vaccines in 2020. This makes the technology primed for being used in other avenues, such as cancer vaccines, Offit said. "We now know a lot about mRNA," he said. "We know a lot about its safety. We know a lot about its safety in young children, including babies. We know a lot about it regarding gene therapy. We know a lot about this safety in terms of pregnant people, where that's often not the case with new technology." Offit went on, "So you have this background of information that enables you to move forward in a number of areas, involving babies or involving pregnant women. But there was an attempt by this administration to squelch that, to sit on all that for no good reason other than a political reason." Solve the daily Crossword
Yahoo
5 minutes ago
- Yahoo
Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2%
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market's revenue expectations , with sales up 16% year on year to $811.1 million. The company's full-year revenue guidance of $3.15 billion at the midpoint came in 1.7% above analysts' estimates. Its non-GAAP profit of $0.22 per share was significantly above analysts' consensus estimates. Is now the time to buy Exact Sciences? Find out in our full research report. Exact Sciences (EXAS) Q2 CY2025 Highlights: Exact Sciences will pay $75 million in cash (plus up to $700 million in additional payments) to secure the rights to Freenome's blood-based screening tools for colorectal cancer. Exact will also pay royalties up to 10% and $20 million annually for the next three years in joint R&D costs Revenue: $811.1 million vs analyst estimates of $773.1 million (16% year-on-year growth, 4.9% beat) Adjusted EPS: $0.22 vs analyst estimates of $0.05 (significant beat) Adjusted EBITDA: $138.2 million vs analyst estimates of $108.7 million (17% margin, 27.2% beat) The company lifted its revenue guidance for the full year to $3.15 billion at the midpoint from $3.10 billion, a 1.8% increase EBITDA guidance for the full year is $465 million at the midpoint, above analyst estimates of $437.4 million Operating Margin: -0.3%, up from -3.8% in the same quarter last year Free Cash Flow Margin: 5.8%, down from 10.2% in the same quarter last year Constant Currency Revenue rose 16% year on year (12.4% in the same quarter last year) Market Capitalization: $8.93 billion 'The Exact Sciences team continues to build momentum, advancing our mission through earlier detection,' said Kevin Conroy, chairman and CEO. Company Overview With a mission to detect cancer earlier when it's more treatable, Exact Sciences (NASDAQ:EXAS) develops and markets cancer screening and diagnostic tests, including its flagship Cologuard stool-based colorectal cancer screening test. Revenue Growth A company's long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Thankfully, Exact Sciences's 21.1% annualized revenue growth over the last five years was excellent. Its growth beat the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Exact Sciences's annualized revenue growth of 13% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. We can better understand the company's sales dynamics by analyzing its constant currency revenue, which excludes currency movements that are outside their control and not indicative of demand. Over the last two years, its constant currency sales averaged 13.3% year-on-year growth. Because this number aligns with its normal revenue growth, we can see that Exact Sciences has properly hedged its foreign currency exposure. This quarter, Exact Sciences reported year-on-year revenue growth of 16%, and its $811.1 million of revenue exceeded Wall Street's estimates by 4.9%. Looking ahead, sell-side analysts expect revenue to grow 11.8% over the next 12 months, similar to its two-year rate. Despite the slowdown, this projection is noteworthy and indicates the market is forecasting success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes. Although Exact Sciences broke even this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average operating margin of negative 29.8% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. On the plus side, Exact Sciences's operating margin rose by 29.2 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming into its more recent performance, however, we can see the company's margin has decreased by 16.6 percentage points on a two-year basis. If Exact Sciences wants to pass our bar, it must prove it can expand its profitability consistently. Exact Sciences's operating margin was negative 0.3% this quarter. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Although Exact Sciences's full-year earnings are still negative, it reduced its losses and improved its EPS by 33.1% annually over the last five years. The next few quarters will be critical for assessing its long-term profitability. In Q2, Exact Sciences reported adjusted EPS at $0.22, up from negative $0.06 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street is optimistic. Analysts forecast Exact Sciences's full-year EPS of negative $0.33 will flip to positive $0.73. Key Takeaways from Exact Sciences's Q2 Results Exact Sciences will pay $75 million in cash and make up to $700 million in additional payments to secure the rights to Freenome's current and future blood-based screening tools for colorectal cancer. Exact will also pay sales royalties up to 10% and $20 million annually for the next three years in joint research and development costs. So do we think Exact Sciences is an attractive buy at the current price? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Associated Press
7 minutes ago
- Associated Press
Stuck astronaut Butch Wilmore retires from NASA less than 5 months after extended spaceflight
CAPE CANAVERAL, Fla. (AP) — One of NASA's two previously stuck astronauts has retired from the space agency, less than five months after his unexpectedly long spaceflight came to an end. NASA announced Butch Wilmore's departure on Wednesday. Wilmore and Suni Williams launched last summer as test pilots on Boeing's first astronaut flight. What should have been a weeklong trip to the International Space Station turned into a stay of more than nine months because of Boeing's malfunctioning Starliner. Starliner came back empty, and Wilmore and Williams returned to Earth in March with SpaceX. Wilmore, 62, had already retired from the Navy. Williams, 59, also a retired Navy captain, is still with NASA. She joined Second Lady Usha Vance at Johnson Space Center in Houston earlier this week, taking part in a summer reading challenge for schoolchildren. Selected as an astronaut in 2000, Wilmore logged 464 days in orbit over three missions. His final spaceflight made up nearly two-thirds of that total: 286 days. 'Throughout his career, Butch has exemplified the technical excellence of what is required of an astronaut,' NASA's chief astronaut Joe Acaba said in a statement. 'As he steps into this new chapter, that same dedication will no doubt continue to show in whatever he decides to do next.' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.